Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018746 | Systemic Inflammatory Response Syndrome NIH | 0.50 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, IL-2, IL-7, IL-10 and TNF-α. In order to elucidate the mechanism of this hyper inflammatory syndrome we will measure a panel of pro and anti inflammatory cytokines, as well as known markers of macrophage activation syndrome. To determine the role of activation of the complement cascade the most important complement factors and their activation markers will be measured. The changes of those parameters will be monitored after administration of an anti-IL6R antibody therapy.
Description: Interleukine 6, soluble IL6-R, complex IL6-IL6R concentration
Measure: IL6 concentration Time: Before anti-IL6R treatment (baseline)Description: Interleukine 6 soluble IL6-R, complex IL6-IL6R variation compared to baseline value
Measure: IL6 concentration change from baseline value Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2
Measure: Complement parameters Time: Before anti-IL6R treatment (baseline)Description: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2 variation compared to baseline values
Measure: Complement parameters change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18
Measure: Inflammatory cytokines baseline concentrations Time: Before anti-IL6R treatment (baseline)Description: Concentration of TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, IL18 variation compared to baseline values
Measure: Inflammatory cytokines change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administrationDescription: sCD25, sCD163, sCD14, glycosylated ferritin
Measure: Concentration of markers of macrophage activation Time: Before anti-IL6R treatment (baseline)Description: sCD25, sCD163, sCD14, glycosylated ferritin variation compared to baseline values
Measure: Markers of macrophage activation change from baseline values Time: Twice a week from day 1 to day 14 post anti-IL6R administrationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports